Leveraging DNA Targeted Technology against Hard-to-Treat Diseases
Oncogenuity uses a targeted gene approach to isolate and displace mutant DNA, with single base pair mismatch sensitivity, that contribute to genetically driven diseases. Our proprietary delivery platform penetrates cells with DNA analogs (ONCOlogues) that are capable of binding to gene sequences 1,000 times more effectively than native DNA.
ONCOlogues are highly specific, with limited off-target toxicity and potentially fewer side-effects than existing drug treatments. This selectivity enables us to target specific mutations in genetically-driven cancers that were once considered to be undruggable, paving the way for new, safe, and effective treatment options.